Technology

Google Ad

Emerging leader in the development of innovative medical diagnostic products TT2 Biosystems will highlight how direct-from-whole blood innovations—the T2Bacteria, T2Candida and T2Resistance panelspositively impact patients with bloodstream infections at Infectious Diseases Conference.

T2 Biosystems

T2 Biosystems antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease.

T2 Biosystems and Clinicians to Share Clinical Data in Integrated Symposium and Poster Presentations at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

Data will highlight how direct-from-whole blood innovations—the T2Bacteria, T2Candida and T2Resistance panels—positively impact patients with bloodstream infections

T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that the Company will host an integrated symposium highlighting key clinical data about the T2Bacteria® and T2Candida® panels at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam on Monday, April 15, at 16:00-18:00 Central European Time (CET). ECCMID will take place April 13-16 at the Amsterdam RAI Exhibition and Convention Center.

Collaborations in medical devices have led to recent advances including neuro-stimulators, stent technologies, biomarkers, robotic assistance, and implantable electronic devices. Since innovation fuels the medical device sector's ongoing quest for better ways to treat and diagnose medical conditions, when coupled with patient life expectancy increasing and aging populations globally, the medical device sector should continue growing at a positive rate in the future."

Medical Technology

T2 Biosystems also recently announced that on March 15, 2019 it issued inducement awards to seven new employees and on April 3, 2019 it issued inducement awards to four new employees.

These awards were made under T2 Biosystems' Inducement Award Plan (the “Inducement Plan”), which was adopted by the company's Board of Directors on March 1, 2018 and amended and restated on February 21, 2019 and provides for the granting of equity awards to new employees of T2 Biosystems.

T2 Biosystems Earnings Release

TTOO will release its 2019 first quarter financial and operational results after the market closes on Thursday, May 2, 2019. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Thursday, May 2, 2019 to discuss the financial results and other business developments.

Cantor Ftizgerald Buy Rating

In a report released April 11 2019, Jordan Abrams from Cantor Fitzgerald reiterated a Buy rating on T2 Biosystems, with a price target of $10. The company’s shares closed on April 10 at $3.08, close to its 52-week low of $2.47.

Abrams noted: “. We reiterate our Overweight rating and 12-month PT of $10 on shares of TTOO. We conducted a 25-person survey of emergency medicine physicians all familiar with T2’s technology to understand physician perspective on T2 Bacteria. On average, our polled physicians think market penetration of T2 Bacteria will grow to 11.1% and 22.2% in one and two years from now, respectively. Significantly, 72% of respondents would clinically change the way he or she treats patients with T2 Bacteria. Physicians think T2 Bacteria is clinically appropriate for 65% of all patients suspected of sepsis, translating to an addressable $313MM annual sepsis diagnostic market.”

About T2 Biosystems:

T2 Biosystems, a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx® Instrument, T2Candida® Panel, and T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease.

From The TradersCommunity Research Desk

Log in to comment
Discuss this article in the forums (0 replies).